• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Belgium·Basic Materials·RES.BR
Share

Resilux N.V. Stocks

€ 0Last Updated 23.03.2026

Issuer Rating

Performance

Modest

Risk

Low

Recommendation

Sell

€ 0
Key Takeaways

Risk factor

Considerable default risk

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Resilux NV manufactures and sells polyethylene terephthalate (PET) preforms and bottles in Europe, Russia, Spain, Switzerland, the United States, and internationally. Its preforms and bottles are used for packaging water, carbonated soft drinks, edible oils, sauces, detergents, milk, beer, juices, fruit juices and fruit drinks, milk, iced tea, and other applications. The company's products are also used to produce wide mouth jars, packaging foils, and blister packs. In addition, it provides in-house, wall-to-wall, and satellite blowing services; and PET recycling services. The company primarily serves producers of drinks, food, and household products. Resilux NV was incorporated in 1992 and is headquartered in Wetteren, Belgium.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E. Editor's note: P/CR is

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.05.2026 15:00

Anthropic will pay nearly $45 billion for access to SpaceX supercomputers

21.05.2026 14:35

The Ebola outbreak has sent shares of biotech GeoVax skyrocketing. It's developing a vaccine

21.05.2026 14:12

Wedbush analyst predicted a Tesla and SpaceX merger in 2027

21.05.2026 12:20

SpaceX IPO will make Elon Musk the world's first and only trillionaire

21.05.2026 11:25

WHO reports hantavirus and a dangerous Ebola outbreak. Will this set off a new vaccine race?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026